Development of an effective inactivated rotavirus vaccine (IRV) for developing countries: definition of rationale, business case, technical feasibility and overall development plan. (360G-Wellcome-099899_Z_12_Z)
Development of an effective inactivated rotavirus vaccine (IRV) for developing countries: definition of rationale, business case, technical feasibility and overall development planThis Pathfinder Award to Dr Audino Podda at the Novartis Vaccines Institute for Global Health in collaboration with Dr Jean-Pierre Amorij at InTraVacc in the Netherlands will provide pilot funding to assess the technical and commercial feasibility of developing a candidate inactivated rotavirus vaccine.The award will be used to assess if this candidate vaccine could provide advantages over existing live vaccines to offer a more effective and lower-cost solution for those most at risk of severe diarrhoea caused by rotavirus infection.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 99913 |
| Applicant Surname | Podda |
| Approval Committee | Technology Transfer Challenge Committee |
| Award Date | 2012-09-17T00:00:00+00:00 |
| Financial Year | 2011/12 |
| Grant Programme: Title | Pathfinder Award |
| Internal ID | 099899/Z/12/Z |
| Lead Applicant | Dr Audino Podda |
| Other Applicant(s) | Dr Jean-Pierre Amorij |
| Partnership Value | 99913 |
| Planned Dates: End Date | 2015-06-02T00:00:00+00:00 |
| Planned Dates: Start Date | 2013-06-03T00:00:00+00:00 |
| Recipient Org: Country | Italy |
| Region | International |